|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 美国临床肿瘤学会IV期非小细胞肺癌化疗的临床实践指南更新显示文摘本文旨在为IV期非小细胞肺癌患者的治疗提供更新版推荐。本文资料检索源自2002年以来公布的相关随机试验文献。此指南范围限于化疗与生物治疗。更新委员会对这些文献进行了总结并提供了推荐更新。162篇文献符合标准被纳入参考。本推荐基于可改善总生存期的治疗方法。仅改善无进展生存期的治疗方法推动了对毒性及生存质量的监测。对于体力状态评分为0分或1分患者的一线治疗,可推荐以铂类为基础的细胞毒性药物的两药联用。对铂类治疗有禁忌的患者,可采用非铂类细胞毒性两药联合。对于体力状态评分为2分的患者,单一细胞毒性药物即可。对于疾病进展或经过4个周期的治疗仍对治疗无反应的患者,应停止一线细胞毒性化疗。即使在6个周期后患者对治疗仍有反应,亦应停止两药细胞毒性化疗。对于伴有明确的表皮生长因子受体(epidermal growth factor receptor,EGFR)突变的患者,可推荐一线采用吉非替尼治疗;对于EGFR突变为阴性或不明确的患者,细胞毒性化疗更佳。除具有特定临床特征的患者外,可推荐贝伐单抗与卡铂-紫杉醇联用。对于通过免疫组化证实EGFR阳性的肿瘤患者,可推荐西妥昔单抗与顺铂-长春瑞滨联用。多西紫杉醇、厄洛替尼、吉非替尼或培美曲塞被推荐作为二线治疗。对于未曾接受过厄洛替尼或吉非替尼治疗的患者,可推荐厄洛替尼作为三线治疗。现有数据不足以推荐常规三线采用细胞毒性药物。已有的证据也不足以推荐常规应用分子标记物选择化疗。 | Christopher G. AZZOLI Sherman Baker JR Sarah TEMIN William PAO Timothy ALIFF Julie BRAHMER David H. JOHNSON Janessa L. LASKIN Gregory MASTERS Daniel MILTON Luke NORDQUIST David G. PFISTER Steven PIANTADOSI Joan H. SCHILLER Reily SMITH Thomas J. SMITH John R. STRAWN David TRENT Giuseppe GIACCONE 丁燕(翻译) 南娟(翻译) 刘谦(翻译) 周清华(校对) 陈军(校对) | 2010 | 中国肺癌杂志2010，13，3： | 43 |
| 2 | Hypersensitivity of human testis2tumor cell lines tochemotherapeutic drugs显示文摘 | Masters JR Osborne EJ Wal Ker MC | 1993 | IntJCancer1993，53，2： | 1 |
| 3 | Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of < lOng/mL显示文摘 | Birtle A J Freeman A Masters JR | 2005 | BJU Int2005，96，3： | 1 |
| 4 | Angiotensin-(1-7) potentiates re- sponses to bradykinin but does not change responses to angiotensin I 显示文摘 | Greco AJ Master RG Fokin A Jr | 2006 | Can J Physiol Pharmacol2006，84，11： | 1 |
| 5 | A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF 显示文摘 | Ahmed T Shea K Masters JR | 2008 | Cell Signal2008，20，7： | 1 |
| 6 | A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF显示文摘 | Ahmed T Shea K Masters JR | 2008 | Cell Signal2008，20，7： | 1 |
| 7 | Direct detec- tion and identification of acid-fast bacteria from smear-positive broth cultures using a pyrosequenc- ing method显示文摘 | Bao JR Clark RB Master RN -et a1 | 2014 | Diagn Microbiol Infect Dis2014，79，2： | 1 |
| 8 | Curing metastatic cancer:lessons from testicular germ-cell tumours显示文摘 | Masters JR Koberle B | 2003 | Nat Rev Cancer2003，3，： | 1 |
| 9 | CD49f is an efficient marker of monolayer and spheroid colony-forming cells of the begin and malignant human prostate显示文摘 | Yamamoto H Master JR Dasgupta P | 2012 | PLos One2012，7，46： | 1 |
| 10 | A PAK4-LIMK1 pathway drives prostate cancer cell migration downstream of HGF 显示文摘 | Ahmed T Shea K Masters JR | 2008 | Cell Signal2008，20，7： | 1 |
| 11 | Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours 显示文摘 | Koberle B Masters JR Hartley JA | 1999 | Curr Biol1999，9，： | 1 |
| 12 | Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax: Bxl - 2 ratio 显示文摘 | Chresta CM Masters JR Hickman JA | 1996 | Cancer Res1996，66，8： | 1 |
| 13 | Hypersensitivity of human testis- tumor cell lines to chemotherapeutic drugs 显示文摘 | Masters JR Osborne EJ Walker MC | 1993 | Int J Cemcer1993，53，2： | 1 |
| 14 | HeLa cells 50 years on:the good,the bad and the ugly显示文摘 | Masters JR | 2002 | Nat Rev Cancer2002，2，4： | 1 |
| 15 | Interferon-γ reduces cell surface expression of annexin 2 and suppresses the inva sire capacity of prostate cancer cells显示文摘 | Hastie C Masters JR Moss SE | 2008 | The Journal of Biological Chemistry2008，283，12： | 1 |
| 16 | Clinical features of patients who present with metastatic prostate carcinoma and serum prostate-specific antigen(PSA) levels <10 ng/mL:the 'PSA negative' patients显示文摘 | Birtle AJ Freeman A Masters JR | 2003 | Cancer2003，98，11： | 1 |
| 17 | Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell turnours 显示文摘 | Koberle B Masters JR Hartley JA | 1999 | Curr Biol1999，9，5： | 1 |
| 18 | Clinical features of patients who present with metastatic prostate carcinoma and serum prostate specific antigen(PSA) levels < 10ug/L: the' PSA negative' patients显示文摘 | Birtle A J Freeman A Masters JR | 2003 | Cancer2003，98，11： | 1 |
| 19 | Clonogenicity : holoclones and mer- oclones contain stem cells 显示文摘 | Beaver CM Ahmed A Masters JR | 2014 | PLoS One2014，9，89： | 1 |
| 20 | Clinical features of patients who present with metastatic prostate carcincm andserum prostatespecific antigen (psa) levels 《 10μg/L,the PSA negative patients显示文摘 | BirtleA J Free man A Masters JR | | 0，，11： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员